BRIEF: Abbisko moves into the black in 2024
Biopharmaceutical company Abbisko Cayman Ltd. (2256.HK) said on Monday that its revenue increased significantly last year, up from 19 million yuan ($2.59 million) in 2023 to 485 million yuan in…
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…
Test results for new cancer drug take Akeso investors on wild ride
Shares in the Chinese pharmaceutical company swung back and forth as investors tried to make sense of clinical trial data for an immunotherapy drug billed as a potential world beater…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.
Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases
Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make…